Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

PHENOS PHENOtyping targeted single-cell via integrated digital microfluidics and optoelectronic tweezerS

Coordinator
Universita Degli Studi Di Roma Tor Vergata, Italy
Runs
10 July 2027 to 9 July 2030
Status
Running
EU funding
€318k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101273477

What the project is doing

In the project's own words, from its summary on CORDIS.

Cellular populations are rich in diversity, and understanding this heterogeneity at the single-cell level is crucial in oncology, where specific subpopulations can drive tumour progression, metastasis, and therapy resistance. PHENOS (“PHENOtyping targeted single-cell via integrated digital microfluidics and optoelectronic tweezerS”) addresses this challenge by introducing the first hybrid platform for targeted single-cell analysis and manipulation.

The system combines digital microfluidics (DMF) for precise liquid handling, aptamer-mediated cell surface functionalization for molecular targeting, optoelectronic tweezers (OET) for non-invasive manipulation, and advanced data analysis algorithms for high-resolution phenotypic profiling. The project is structured in four phases: (1) design and validation of DMF and OET devices, (2) integration into a hybrid opto-microfluidic platform, (3) targeted cell functionalization and longitudinal phenotyping through time-lapse imaging, and (4) development of machine learning and deep learning algorithms for classification and phenotypic stratification.

Through a comprehensive and synergistic training programme bridging engineering, biology, chemistry, and computational science, PHENOS will: (1) establish a dynamic, high-precision workflow for single-cell measurement and sorting, and (2) enhance OET sensitivity and specificity, achieving ≥95% classification accuracy, in independent experiments, with an expected 20% gain from aptamer targeting. By overcoming current limitations, PHENOS will establish a novel framework for decoding cellular heterogeneity in cancer with a decision-making process, guiding personalised treatments and improving patient outcomes, while providing me a unique multidisciplinary environment to build scientific independence and long-term leadership.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di Roma Tor VergataRomaItalyCoordinator
The Governing Council of the University of TorontoTorontoCanadaAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI